ScinoPharm Reports Record-high Performance

ScinoPharm Reports Record-high Performance

2007/10/15

ScinoPharm Reports Record-high Performance

 

Profits and revenue in first nine months of 2007 already surge past record 2006 performance.

Active pharmaceutical ingredient (API) specialist ScinoPharm reported record revenue and profits for the first nine months of 2007, ended 30 September 2007.

Highlights:

  • Total revenue for Jan-Sept 2007 surged to $46.7 million. To-date revenue has already exceeded entire 2006 record revenue of $44.9 million.

  • Jan-Sept 2007 revenue of $46.7 million, an increase of 48 percent from $31.5 million in Jan-Sept 2006.

  • Net income (before taxes) grew to record $7.7 million, an increase of over 600% from $1.1 million in Jan-Sept 2006.

  • To-date 2007 net income is already 3 times total 2006 net income.

  • September 2007 sales reached $9.7 million, highest in the company’s 10-year history.



    •  
  •  

"Our business strategy, which is focused on building a strong portfolio of oncology products and a growing base of global customers, continues to drive record performance." said Dr. Jo Shen, President and CEO of ScinoPharm. “Other factors, including steadier revenue streams from more commercialized products, and improved margins and reduced costs in manufacturing, also contributed to the company’s strong results."

ScinoPharm, specializing in cytotoxic and high potent APIs, has grown from a regional to a global API manufacturer with significant market presence in the supply of oncology APIs worldwide.

To acquire new orders, the company has acted swiftly in worldwide regulatory registrations of the drug master file (DMF) for its APIs. ScinoPharm recently completed one additional US DMF registration for its oncology API Topotecan HCl, bringing its total US regulatory registrations to 23 and worldwide registrations to over 240.

About ScinoPharm Taiwan

ScinoPharm Taiwan Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With cGMP production facilities, ScinoPharm offers a full spectrum of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry. The company currently serves more than 160 customers worldwide. To date, it has over 240 DMF registrations worldwide, 23 of which were filed in the US. For more information, please visit the company’s web site at http://www.scinopharm.com.

 

Contact:

Jessie Wang
Tel: +886-6505-2888
Email: Jessie.Wang@scinopharm.com.tw